Loading…
Celularity Inc. is projected to decline to $0.7073 by 2027, a -4% move from its current price of $0.7404. CELU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.6964 | $0.7399 | $0.7861 | -0.07% |
| Jul 13 | $0.6787 | $0.7394 | $0.8054 | -0.14% |
| Jul 14 | $0.6653 | $0.7388 | $0.8205 | -0.21% |
| Jul 15 | $0.6541 | $0.7383 | $0.8334 | -0.28% |
| Jul 16 | $0.6444 | $0.7378 | $0.8448 | -0.35% |
| Jul 17 | $0.6357 | $0.7373 | $0.8551 | -0.42% |
| Jul 18 | $0.6278 | $0.7368 | $0.8648 | -0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6278 | $0.7368 | $0.8648 | -0.49% |
| Week 2 | $0.5846 | $0.7332 | $0.9196 | -0.97% |
| Week 3 | $0.5529 | $0.7296 | $0.9629 | -1.46% |
| Week 4 | $0.5271 | $0.7261 | $1.00 | -1.94% |
| Week 5 | $0.505 | $0.7225 | $1.03 | -2.42% |
| Week 6 | $0.4857 | $0.719 | $1.06 | -2.89% |
| Week 7 | $0.4684 | $0.7155 | $1.09 | -3.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Celularity Inc. is a cellular and regenerative medicine company focusing on aging-related disease using novel therapies. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for autoimmune Crohn's and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy.
The company also produces, sells, and licenses products used in surgical and wound care markets under brands such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; LifebankUSA collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies. Celularity was founded in 1998 and is headquartered in Florham Park, New Jersey.
Celularity Inc. (CELU) is a healthcare company focused on cellular and regenerative medicine. It currently trades at $0.7267 per share and has a market capitalization of $21.04M, ranking 4903 by market cap.
The stock sits in the Healthcare category and shows a low-priced profile with notable volatility. The forecasted price path presents a range of possible outcomes through 2050, with the 2026 average price at $0.7267 and a broad spread in future years. These figures are estimates and not guarantees.
A major floor 55.3% below — a decisive break under it would weaken the trend.
The nearest floor, 19.2% below — buyers have tended to step in here.
The nearest ceiling, 44.5% above — a clean break opens room to run.
A major ceiling 89.1% above — clearing it would confirm fresh momentum.
Key CELU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CELU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.749 | Sell | $0.7275 | Buy |
| MA 10 | $0.6793 | Buy | $0.7127 | Buy |
| MA 20 | $0.7044 | Buy | $0.7295 | Buy |
| MA 50 | $0.817 | Sell | $0.8364 | Sell |
| MA 100 | $1.04 | Sell | $1.01 | Sell |
| MA 200 | $1.35 | Sell | $1.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.77 | Neutral |
| Stoch RSI (14) | 77.87 | Neutral |
| CCI (20) | 43.45 | Neutral |
| Williams %R (14) | -29.70 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 5.71 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 70.30 | Neutral |
| TRIX (15) | -1.01 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 61.44 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.77 | Sell |
| ADX (14) | 19.94 | Neutral |
| ATR (14) | 0.04 | Info |
The technical picture is NEUTRAL, with RSI(14) at 50. The 50-day SMA is $0.8354 and the 200-day SMA is $1.37, indicating near-term resistance above the current level and a nearby moving-average cushion.
Support is at $0.598 and resistance at $1.07, framing a constrained near-term range around the current price. The 30-day range spans from $0.4701 to $1.12, underscoring a broad swing in the last month. Annualized volatility sits at 100%, highlighting elevated upside and downside risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.598 | $0.7404 | $0.9055 | 0% | Neutral | |
| $0.5131 | $0.7073 | $1.05 | -4% | Neutral | |
| $0.6555 | $0.9603 | $1.53 | +30% | Bullish | |
| $0.6582 | $1.02 | $1.69 | +37% | Bullish | |
| $0.6399 | $1.04 | $1.80 | +40% | Bullish | |
| $0.5994 | $1.01 | $1.82 | +37% | Bullish | |
| $0.48 | $0.8466 | $1.57 | +14% | Neutral | |
| $0.5167 | $0.9489 | $1.81 | +28% | Bullish | |
| $0.612 | $1.17 | $2.28 | +58% | Bullish | |
| $0.684 | $1.36 | $2.71 | +83% | Bullish | |
| $0.7118 | $1.58 | $3.47 | +114% | Bullish | |
| $1.01 | $2.24 | $5.15 | +202% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.598 | $0.7404 | $0.8616 | +0.00% |
| August 2026 | $0.548 | $0.6641 | $0.8383 | -10.31% |
| September 2026 | $0.5653 | $0.6947 | $0.8952 | +4.61% |
| October 2026 | $0.5593 | $0.6958 | $0.9122 | +0.15% |
| November 2026 | $0.5168 | $0.6495 | $0.8639 | -6.65% |
| December 2026 | $0.5294 | $0.6719 | $0.9055 | +3.44% |
Click any year to see its month-by-month CELU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CELU to range from $0.598 to $0.9055 through 2026. The $0.7404 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CELU price prediction for 2027 points to an average of $0.7073 (low $0.5131, high $1.05) — a potential decline of -4% on today's $0.7404. A consolidation phase looks the most probable path here.
In 2028, CELU is projected to trade between $0.6555 and $1.53, averaging $0.9603 — a potential gain of +30% from today's $0.7404. That is up +36% on the projected 2027 average. Momentum favours further upside here.
Celularity Inc.'s 2029 outlook centres on $1.02, within a $0.6582 to $1.69 range. That is up +6% on the projected 2028 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CELU could reach as high as $1.80, with a base case around $1.04 and support toward $0.6399 — roughly +40% from $0.7404. Momentum favours further upside here.
Expect CELU to range from $0.5994 to $1.82 through 2031. The $1.01 average target implies a +37% move from current prices. That is -2% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The CELU price prediction for 2032 points to an average of $0.8466 (low $0.48, high $1.57) — a potential gain of +14% on today's $0.7404. Price action looks broadly range-bound.
In 2033, CELU is projected to trade between $0.5167 and $1.81, averaging $0.9489 — a potential gain of +28% from today's $0.7404. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Celularity Inc.'s 2034 outlook centres on $1.17, within a $0.612 to $2.28 range. That is up +23% on the projected 2033 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2035, CELU could reach as high as $2.71, with a base case around $1.36 and support toward $0.684 — roughly +83% from $0.7404. Buyers look set to stay in control over this stretch.
Expect CELU to range from $0.7118 to $3.47 through 2040. The $1.58 average target implies a +114% move from current prices. That is up +16% on the projected 2035 average. Momentum favours further upside here.
The CELU price prediction for 2050 points to an average of $2.24 (low $1.01, high $5.15) — a potential gain of +202% on today's $0.7404. Buyers look set to stay in control over this stretch.
Investing $1,000 in CELU today (≈ 1,350.621286 CELU) could be worth
$3,023.54
+$2,023.54 (+202%) by 2050 · US Dollar
Based on the average projected CELU price of $2.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CELUwould be worth at today's price.
$1,000 invested in CELU on Jul 10, 2025 (≈ 462.962945 CELU) would be worth
$342.78
-$657.22 (-65.7%) today · 0.34× · US Dollar
Based on a CELU entry price of $2.16 vs. today's $0.7404.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.62 | $1,194.19 | +19.4% |
| 1 month ago | $0.774 | $956.59 | -4.3% |
| 3 months ago | $1.27 | $582.99 | -41.7% |
| 6 months ago | $1.32 | $560.91 | -43.9% |
| 1 year ago | $2.16 | $342.78 | -65.7% |
| All time (5.0y) ago | $101.9 | $7.27 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CELU forecast.
Our base-case forecast reaches $1.50 around 2040.
Implied market cap at $1.50: $43.42M
The multi-year forecast moves from neutral in 2026–2027 to bullish thereafter, with meaningful upside projected through 2050. In 2026, the avg price is $0.7267 with ROI 0 and neutral sentiment; by 2028 the avg rises to $0.9056 with ROI 24.6 and a bullish tone, continuing through 2029 (avg $0.9776, ROI 34.5) and 2030 (avg $0.9916, ROI 36.5).
The uptrends extend into 2034 (avg $1.09, ROI 49.4) and 2035 (avg $1.29, ROI 77) with bullish sentiment, then peak in 2040 (avg $1.45, max $3.18, ROI 99.4). By 2050, the avg price is projected at $2.11 with a max of $4.85 and ROI of 190.2%, continuing a bullish sentiment. These are estimates and not guarantees, and actual results may differ due to market conditions and other factors.
The long-term upside comes with substantial risk and volatility given the high variance in the forecasts.
Tap a question to reveal the answer.
In 2030, the forecast shows min $0.6127, avg $0.9916, max $1.72 and ROI 36.5% with bullish sentiment.
The 2026 forecast shows avg price $0.7267 with ROI 0 and neutral sentiment; later years show bullish sentiment from 2028 onward with several positive ROIs (24.6% in 2028, 34.5% in 2029, up to 190.2% by 2050). These are estimates and not guarantees.
Yes. The forecast maximums exceed $2 in multiple years: 2034 max $2.12, 2035 max $2.57, 2040 max $3.18, and 2050 max $4.85, suggesting potential above $2 according to the forecast.
Current price is $0.7267 and market cap is $21.04M.
The 2026 forecast lists min $0.598, avg $0.7267, max $0.8957 with ROI 0 and sentiment NEUTRAL.
Celularity Inc. Community Discussion
0Share your Celularity Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.